Opinion|Videos|May 16, 2025
CD4 T-cell and Lymphocyte Monitoring: Clinical Significance in HIV Treatment
Author(s)Sharon Walmsley, CM, MD, FRCPC
A panelist discusses how CD4 counts serve as measures of immune system status that typically increase by about 200 in the first year of antiretroviral therapy. Although there can be laboratory variability, these counts remain important for patient monitoring and identifying those at risk for complications.
Advertisement
CD4 T-Cell Monitoring in HIV Management
Key Themes:
- Immune Reconstitution: Average CD4 count increases of approximately 200 cells in the first year of effective therapy
- Laboratory Variability: CD4 count fluctuations of up to 20% between measurements, causing potential patient concern
- Clinical Utility Debate: Discussion of whether routine CD4 monitoring remains necessary in stable patients
- Toxicity Monitoring: Importance of CD4 count monitoring in trials of new agents with potential lymphotoxicity
Notable Insights from Dr Sharon Walmsley:
- Despite some recommendations to reduce CD4 monitoring (“choosing wisely” initiatives), many patients value these numbers as reinforcement that treatment is working.
- CD4 counts remain important for guiding opportunistic infection prophylaxis decisions in patients with lower values.
- CD4 monitoring can serve as a motivational tool for patients struggling with adherence.
- In switch studies, CD4 counts typically remain stable when patients are already virologically suppressed.
Advertisement
Related to this article
Michael Mina, MD, PhD, explains which adverse events drove VYD2311's edge vs an mRNA COVID-19 vaccine and who may benefit most.
The FDA approves atezolizumab with a fluoropyrimidine and oxaliplatin as adjuvant therapy for stage III dMMR colon cancer based on the ATOMIC trial.
Michael Mina, MD, PhD, explains Invivyd's accelerated approval path for VYD2311 and how it could change the timing of COVID-19 protection.
Biomarker-driven care is advancing in mantle cell lymphoma, though cost and infrastructure limit access in community oncology, according to a review.
Fibrosis stage, not MASH resolution, best predicts mortality, which should shape trial end points, says Georgetown's Zobair Younossi, MD, MPH.
Remibrutinib (Rhapsido; Novartis) is the only treatment with approved uses in both chronic spontaneous urticaria and symptomatic dermographism.
Lean MASLD shows milder histology than overweight and obese MASLD but similar mortality and event risk, with fibrosis tied to prognosis.
Hepatitis reports after vaccination were more often serious in children, but the data lack dose counts and cannot show vaccine-specific risk.
Advertisement
Advertisement
Trending on AJMC
1
5 Things to Know if Retatrutide Is Classified as a Biologic
2
FDA Approves IV, Subcutaneous Atezolizumab for dMMR Colon Cancer
3
FDA Approves First Symptomatic Dermographism Treatment
4
Predoc and Nebraska Cancer Specialists: Not Letting the Fax Be the Fumble
5